Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048100 · ClinicalTrials.gov registry record · Phase 1
Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00048100: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00048100 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00048100, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Objectives: 1. Determine the toxicity of infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL) in relapsed patients after allo-stem cell transplants. 2. Quantitate the alloreactivity of DC/ADL and circulating immune effector cells in patients after infusion. 3. Assess efficacy of acute myelogenous leukemia (AML) or Chronic Myelogenous Leukemia in Blastic Crisis (CML-BC) derived dendritic cells and activated lymphocytes in promoting and sustaining remission in patients with relapse after allo-BMT or stem cell transplant.
Interventions
- PROCEDURE Apheresis
- BIOLOGICAL Stem Cell Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2001-02 |
| Est. Completion | 2005-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048100
The ClinicalTrials.gov registry entry for NCT00048100 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apheresis is the first listed.
NCT00048100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048100 about?
NCT00048100 is a clinical study titled "Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes". Objectives: 1. Determine the toxicity of infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL) in relapsed patients after allo-stem cell transplants. 2. Quantitate the alloreactivity of DC/ADL and circulating immune effector cells in patients after i...
What is the current status of trial NCT00048100?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2001-02. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00048100?
The interventions under investigation include: Apheresis (PROCEDURE), Stem Cell Transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT00048100?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.